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Abstract
Background: Branchio-oto-renal (BOR) or branchio-otic (BO) syndrome is one of the most common forms of autosomal
dominant syndromic hearing loss. Mutations in EYA1, SIX1 and SIX5 genes have been associated with BOR syndrome. In this
study, clinical and genetic analyses were performed in patients with BOR/BO syndrome focusing on auditory manifestations
and rehabilitation.
Methods: The audiologic manifestations were reviewed in 10 patients with BOR/BO syndrome. The operative findings and
hearing outcome were analyzed in patients who underwent middle ear surgeries. The modality and outcome of auditory
rehabilitation were evaluated. Genetic analysis was performed for EYA1, SIX1, and SIX5 genes.
Results: All patients presented with mixed hearing loss. Five patients underwent middle ear surgeries without successful
hearing gain. Cochlear implantation performed in two patients resulted in significant hearing improvement. Genetic analysis
revealed four novel EYA1 mutations and a large deletion encompassing the EYA1 gene.
Conclusions: Auditory rehabilitation in BOR/BO syndrome should be individually tailored keeping in mind the high failure
rate after middle ear surgeries. Successful outcome can be expected with cochlear implantations in patients with BOR/BO
syndrome who cannot benefit from hearing aids. The novel EYA1 mutations may add to the genotypic and phenotypic
spectrum of BOR syndrome in the East Asian population.
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Introduction
Branchio-oto-renal (BOR) syndrome (OMIM 113650) or
branchio-otic (BO) syndrome (OMIM 602588) is one of the most
common forms of autosomal dominant syndromic hearing loss
with an incidence of 1:40,000 and is responsible for causing 2% of
profoundly deaf children [1]. The clinical manifestations of BOR
syndrome include hearing loss (93%), preauricular pits or tags
(82%), renal anomalies (67%), branchial fistulae (49%), and pinnae
deformity (36%) [2]. Diagnostic criteria proposed by Chang et al.
[3] in 2004 are most widely used for the clinical diagnosis of BOR
syndrome. In 1997, Abdelhak et al. [4] reported the human
homolog of the Drosophila eyes absent gene (EYA1) as the causative
gene of BOR syndrome and identified novel mutations of the
EYA1 gene in seven families demonstrating typical features of
BOR syndrome. Mutations of the EYA1 gene are found in
approximately 40% of patients with BOR syndrome [3]. In
addition to the EYA1 gene, mutations in the SIX1 and SIX5 genes
have been reported to cause BOR phenotypes, although the
pathogenic role of the SIX5 gene has been questioned recently
[5,6,7]. SIX1 mutations have been shown to disrupt the EYA1-
SIX1-DNA complexes [5,8].
The EYA1 gene located on chromosome 8q13.3 encodes a
transcriptional co-activator required for eye morphogenesis which
consists of three isoforms (a, b, c) and four transcript variants
(EYA1A–1D) as a result of alternative splicing [9,10]. EYA1C
(transcript variant 3; NM_000503), one of the two variants of
isoform b, is the longest transcript encoded by 16 coding exons
extending over 156 kb [10].
To date, approximately 160 mutations of the EYA1 gene have
been associated with BOR/BO syndrome, and frameshift or
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nonsense mutations are the most commonly detected mutations,
followed by splice-site and missense mutations
[7,11,12,13,14,15,16,17]. Approximately 20% of the patients with
BOR/BO syndrome have been reported to be caused by complex
genomic rearrangements of the EYA1 gene that are not detected
by direct sequencing of the coding region [3]. No specific hot spot
has been demonstrated for EYA1 mutations causing BOR
syndrome and most of the mutations are unique to individual
families [3].
Hearing impairment, the most common phenotypic feature of
BOR syndrome, is found in various forms among which mixed
type of hearing loss is most frequently reported (50%), followed by
conductive (30%) and sensorineural type (20%) [2]. Analysis of
computed tomography (CT) imaging of the temporal bone has
revealed malformations of the middle and inner ear structures in
majority of the patients with BOR syndrome [2,18]. Chen et al. [2]
found cochlear hypoplasia (63%), enlarged vestibular aqueduct
(46%), bulbous internal auditory canal (25%), and ossicular
malposition (50%) or malformation (33%), while Propst et al.
[18] described hypoplastic apical turn of cochlea (100%), medial
deviation of the facial nerve (90.5%), and funnel shaped internal
auditory canals (85.7%) as the most common findings of the
temporal bone in patients clinically diagnosed as BOR syndrome.
Because of the conductive component of hearing loss identified
in most cases of patients with BOR syndrome, attempts have been
made to improve hearing through middle ear exploratory
tympanotomy and ossicular reconstruction. However, there are
only several studies dealing with hearing outcome of exploratory
tympanotomy in patients with BOR syndrome mostly reported
before the identification of genetic causes of BOR syndrome,
which demonstrated unsatisfactory results [19]. Since variable
clinical manifestations concerning onset, degree, type, and
progressiveness of hearing loss can be seen in BOR syndrome,
auditory rehabilitation in these patients have to be carefully
evaluated and managed according to individual conditions. In this
study, clinical analysis was performed in 10 patients with BOR/
BO syndrome focusing on auditory manifestations and rehabili-
tation, and the results of mutational analysis for the EYA1, SIX1,
and SIX5 genes are reported.
Materials and Methods
Subjects
Seven families (10 patients) including one multiplex family
showing hearing loss and one or more of the typical features of
BOR syndrome were included in this study for clinical and genetic
analyses. The clinical diagnosis as typical BOR syndrome was
made when the clinical criteria proposed by Chang et al. [3] were
satisfied, whereas atypical BOR syndrome was diagnosed when
only one or two features of BOR syndrome were present together
with hearing loss. The combined anomalies were thoroughly
reviewed in all patients; however, the results of renal ultrasonog-
raphy were available in 4 of 10 patients. Written informed consent
was obtained from the participating individuals, and this study was
approved by the Institutional Review Board of the Yonsei
University College of Medicine.
Audiologic Evaluation
Serial pure tone audiometries were performed in all patients
and the various clinical manifestations regarding hearing loss were
carefully reviewed. The type, degree, onset, progressiveness and/
or fluctuation of hearing loss were evaluated in each patient. The
threshold of pure tone audiometry was defined as the average of
thresholds at 500, 1000, 2000, and 3000 Hz. The follow-up period
of audiologic evaluations ranged from 3 months to 7.5 years.
Speech audiometry and language evaluations were carried out in
some of the patients whenever possible.
Radiologic Evaluation
The temporal bone CT scan was performed in all of 10 patients
and temporal magnetic resonance imaging (MRI) was available for
analysis in 4 patients. The temporal bone CT scan was performed
with a 16 multidetector row CT scanner (Somatom Sensation 16;
Siemens, Erlangen, Germany) using a standard temporal bone
protocol. Contiguous 0.7-mm scans of the temporal bone were
acquired in the axial plane and reformatted coronally with 1.0-
mm increments. CT images were performed, digitally stored, and
displayed by using the Picture Archiving Communication System
(PACS) (Centricity; GE Healthcare, Milwaukee, WI).
MRI was acquired by using a 3.0-T (Achieva; Philips Medical
Systems, Best, the Netherlands) or 1.5-T system (Intera; Philips
Medical Systems, Best, the Netherlands) with a six-channel
sensitivity encoding (SENSE) head coil. The targeted parasagittal
scan perpendicular to the long axis of the internal auditory canal
was obtained with T2-weighted three-dimensional (3-D) turbo
spin-echo (TSE) sequence with driven equilibrium RF reset pulse
(DRIVE), following routine MR sequences with spin-echo T1- and
T2-weighted images. The sequence parameters for the T2-
weighted 3-D FSE sequence with DRIVE were as follows:
repetition time (TR)/echo time (TE) = 1500/200 ms, 256 acqui-
sition/256 reconstruction, 15-cm field of view, 1.5-mm section
thickness with a 0.75-mm overlap, number of acquisitions = 2, and
the scan time was less than 5 minutes.
The morphologies of the cochlea, vestibule, semicircular canals,
internal auditory canals, vestibular aqueduct, and middle ear
structures were analyzed on temporal bone CT scans. On
temporal MRI, abnormalities of the brain, the cochleovestibular
and facial nerves, as well as the endolymphatic duct and sac were
evaluated.
Gene Screening
All exons and exons-intron boundaries of EYA1, SIX1 and SIX5
gene were amplified by Polymerase Chain Reaction (PCR) with
specific primers (Table S1) designed using Primer 3 software
(http://frodo.wi.mit.edu/). PCR with H taq polymerase (Solgent,
Daejeon, South Korea) proceeded as following cycles: 15 minutes
at 95uC, repeated of 30–40 cycles of denaturation at 94uC for 20
seconds; annealing at * uC for 40 seconds; extension at 72uC for 30
seconds (* is depended by melting temperature of primers). Last
extension step was performed at 72uC for 5 minutes. Particularly,
exons 1 and 2 of SIX5 were amplified using LA taq (TaKara, Otsu,
Shiga, Japan), because these regions have high GC contents. PCR
products were separated on 1.5% agarose gel. The PCR products
were purified using Shrimp alkaline phosphatase (USB, Cleveland,
OH, USA) and exonuclease I at 37uC for 70 minutes and directly
sequenced using the Bigdye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA). Ethanol
precipitation was used for purification of sequencing reaction
products before running the samples on the 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA). The data
was analyzed utilizing Sequencing analysis v5.2 (Applied Biosys-
tems, Foster City, CA, USA) and Chromas Pro v1.5 software
(Technelysium, Pty Ltd., Tewantin, QLD, Australia). Multiple
alignments of the analyzed sequences were performed using CLC
sequence Viewer v.6.0 software (CLC Bio, Aarhus, Denmark).
Molecular and Clinical Analyses of BOR/BO Syndrome
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e67236
Splicing Assays
To analyze the splicing pattern, minigene vector was manufac-
tured to include each exon along with about 300 bp of 59- and
300 bp of 39- intronic flanking regions (c.699+5 G.A,
c.1140+1 G.A, c.1598-2 G.A). Amplified wild or mutant type
products digested with BamHI and EcoRI were inserted into
multiple cloning sites between exon A and exon B in pSPL3 or
pSPL3b vectors. For in vitro splicing assay, HeLa cells were
cultured in DMEM (containing 10% FBS, 1% Penicillin/
Streptomycin) at 37uC in 5% CO2 concentration. Prior to
transfection, HeLa cells were seeded at a density of 2.76106 on
a 60 mm culture dish. Hybrid minigenes in pSPL3 or pSPL3b
vector were transiently transfected into HeLa cells using Fugene 6
Transfection reagent (Promega, Madison, WI, USA) at 3 mL per
mg of DNA, and the transfected cells were harvested 24 hours after
transfection. Total RNA was extracted from the transfected HeLa
cells using an RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Approximately 1 mg of
total RNA was reverse-transcribed into cDNA using a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). The cDNA was used as a template for
PCR amplification of pSPL3 or pSPL3b vector-specific primers
SD6 and SA2. The size of amplified normal and mutant fragments
was confirmed on 1.5% agarose gel by electrophoresis.
Multiplex Ligation-dependent Probe Amplification
Multiplex Ligation-dependent Probe Amplification (MLPA) was
performed to detect copy number variations such as deletions or
duplications. The SALSA MLPA probemix P153-A2 EYA1 kit
(MRC-Holland, Amsterdam, The Netherlands) that was used
includes 17 probes for 14 of the 18 EYA1 exons (probes for exons
1, 8, 13, 16 are not included whereas two different probes exist for
exons 6, 9, 10) and 14 control probes. MLPA was performed
according to the manufacturer’s instructions: denaturation at 98uC
for 5 minutes; stabilization at 25uC; hybridization at 95uC for 1
minute and at 60uC for 16–20 hours, stabilization at 54uC; ligation
at 54uC for 15 minutes, inactivation at 98uC for 5 minutes, and
stabilization at 20uC. PCR was carried out as follows: 35 cycles of
denaturation at 95uC for 30 seconds; annealing at 60uC for 30
seconds; extension at 72uC for 1 minute. Final extension step was
performed at 72uC for 20 minutes. Amplified products containing
GeneScanTM-500 LIZH Size Standard (Applied Biosystems, Fos-
ter City, CA, USA) and Hi-Di Formamide (Applied Biosystems,
Forster City, CA, USA) were separated and quantified by capillary
electrophoresis on the 3130xl Genetic Analyzer (Applied Biosys-
tems, Forster City, CA, USA), and the data were analyzed using
GeneMarker software v1.6 (Softgenetics, State College, PA, USA).
Genotype Analysis of Microsatellite Markers
Four microsatellite markers, D8S1795, D8S1060, D8S1807 and
D8S570, in the region of 2 Mb including the EYA1 gene were
selected from the NCBI database (www.ncbi.nlm.gov) considering
their heterozygosity. PCR with H taq polymerase was performed
using fluorescently tagged primers. Two PCR products of different
fragment size and 0.1 mL of GeneScanTM-500 LIZH Size
Standard (Applied Biosystems, Foster City, CA, USA) were mixed
and diluted with 8.9 mL of Hi-Di Formamide (Applied Biosystems,
Forster City, CA, USA). Final diluted products were separated and
detected by using ABI 3130x genetic analyzer. GeneMapper v4.0
software (Applied Biosystems, Forster City, CA, USA) was used to
analyze genotypes for each marker.
Results
Clinical Presentations
Seven families including 10 patients were analyzed. All of the
patients were females and their age at the time of diagnosis ranged
from 1 to 43 years (Table 1). The clinical features identified in
each patient are shown in Table 2. Nine patients were diagnosed
as typical BOR/BO syndrome according to the criteria by Chang
et al. [3], while one patient exhibited only mixed type of hearing
loss and inner ear anomalies to be classified as atypical BOR/BO
syndrome. Of the major criteria other than hearing loss,
preauricular pit was the most common finding seen in 80%,
followed by branchial anomalies present in 30% of the patients.
Patient 6 aged 14 years and patient 10 aged 43 years had received
excision of bilateral branchial fistulae at other hospitals in
childhood, and demonstrated postoperative scars bilaterally along
the anterior border of the sternocleidomastoid muscle. Patient
9 aged 1 year exhibited nondischarging pits also at the anterior
border of the sternocleidomastoid muscle bilaterally without any
palpable cystic portion. Of the minor criteria, inner ear and
middle ear anomalies detected on temporal bone CT were
identified in all of the patients, whereas external ear anomalies
were observed in only 2 patients.
Results of renal manifestations were evaluated in 4 of 10
patients. In one patient (patient 9), a tiny cyst was seen in the right
renal cortex and mild pelvic dilatation of the right kidney was
identified by renal ultrasonography without any evidence of renal
dysfunction. The other three patients did not reveal any
abnormality on renal ultrasonography or blood testing.
Radiologic Findings and Temporal Bone Anomalies
All of the patients with BOR/BO syndrome underwent high
resolution temporal bone CT, and temporal MRI was available
for analysis in four of the patients (Table 3). Cochlear hypoplasia,
enlarged vestibular aqueduct, and facial nerve anomaly were seen
in all of the patients (Fig. 1). In all patients, cochlea demonstrated
less than two turns consistent with cochlea hypoplasia type III
(Fig. 1A) [20]. The modiolus was present but defective in all
patients (Fig. 1D). The enlarged vestibular aqueduct was often
observed as a circular shape with a diameter significantly larger
than the posterior semicircular canal in the axial section of the
temporal bone CT, which differed from the characteristic funnel-
shaped enlargement of vestibular aqueduct seen in patients with
SLC26A4 mutations (Fig. 1B, Fig. S1). This finding could be
related to the pathologic condition in which the main portion of
enlargement is the endolymphatic duct rather than the endolym-
phatic sac. The MRI performed in 4 of the patients supported this
speculation demonstrating bilateral dilation of the endolymphatic
duct without enlarged endolymphatic sac in two patients and with
unilateral mildly enlarged endolymphatic sac in two patients
(Table 3, Fig. S1). The facial nerve ran inferior to the hypoplastic
cochlea and displayed an obtuse angle between the labyrinthine
and tympanic segments (Fig. 1C). Bulbous or funnel-shaped
internal auditory canals were identified in 5 patients (50%). The
vestibule was dilated bilaterally in all patients and severe lateral
semicircular canal dysplasia was found unilaterally in one of the
patients (patient 2). The ossicular chain was malformed or
malpositioned to variable degrees in all of the patients, and the
fusion of the malleoincudal joint and/or ossicular ankylosis to the
epitympanic wall were present in five patients (patients 1–4, 9)
(Fig. 1E). None of the patients exhibited obliteration of the oval
window or round window on temporal bone CT.
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Auditory Manifestations
Serial pure tone audiometries revealed variable patterns of
hearing loss. All patients presented with mixed type of hearing loss
ranging from moderate to profound degree (Table 1). The onset
was mostly perilingual or postlingual although congenital hearing
loss was demonstrated in two of the patient. Five of 10 patients
presented variable degrees of progressive hearing loss. Two of
these patients showing progressive hearing loss experienced
sudden aggravation of hearing loss, one of whom improved
hearing after steroid treatment (patient 10) while the other became
profoundly deaf without significant improvement despite steroid
treatment (patient 7). Of the five patients showing stable hearing
loss without significant progression over a period of two to four
years, four patients were members of a single family.
Middle Ear Surgeries and Auditory Rehabilitation
For auditory rehabilitation, five of 10 patients underwent
middle ear surgeries (Table 1). In patient 5, ossiculoplasty was
initially performed on the right ear to correct the conductive
component of hearing loss, during which incudostapedial joint was
found separated. Partial ossicular replacement prosthesis (PORP)
was inserted between the stapes and malleus handle. However,
revision ossiculoplasty was performed after 8 months due to failure
of hearing gain and the location of the previously inserted PORP
Table 1. Auditory manifestations and management of hearing loss in patients with BOR/BO syndrome.
Families Patients Sex/Age*(Yr)Auditory manifestations Middle ear surgery
Auditory
rehabilitation
Type
PTA thresholds (dB
HL) Onset Progression HA CI
I 1 F/2 Mixed 80 (R), 60 (L) Congenital No – (B)
2 F/14 Mixed 65 (R), 90 (L) Postlingual No – (B)
3 F/16 Mixed 60 (R), 75 (L) Postlingual No – (B)
4 F/38 Mixed 90 (R), 85 (L) Postlingual No – (B)
II 5 F/12 Mixed 55 (R), 45 (L) Postlingual Yes Ossiculoplasty (R),
stapedotomy (R)
(B)
III 6 F/14 Mixed 65 (R), 65 (L) Postlingual Yes Ossiculoplasty (R) (B) CI (R)
IV 7 F/13 Mixed 90 (R), 105 (L) Postlingual Yes – (B) CI (R)
V 8 F/9 Mixed 50 (R), 50 (L) Congenital No Ossiculoplasty (L) (B)
VI 9 F/1 Mixed 50 (R), 75 (L) Prelingual Yes Cholesteatoma removal (R) (B)
VII 10 F/43 Mixed 65 (R), 60 (L) Postlingual Yes Stapedotomy (B) (B)
*Age at first visit to our clinic; Yr: year; PTA: pure tone audiometry; dB HL: decibel hearing level; HA= hearing aid; CI = cochlear implantation; R: right, L: left, B: both.
doi:10.1371/journal.pone.0067236.t001
Table 2. Clinical features and diagnostic criteria in patients with BOR/BO syndrome.
Clinical Features Patients
1 2 3 4 5 6 7 8 9 10
Major Critieria
Branchial anomalies – – – – – O – – O O
Deafness O O O O O O O O O O
Preauricular pits O O O O O O – O O -
Renal anomalies* ? ? ? ? ? – ? – O –
Minor Criteria
External ear anomalies O – – – O – – – – –
Middle ear anomalies O O O O O O O O O O
Inner ear anomalies O O O O O O O O O O
Preauricular tags – – – – – – – – – –
Other: facial asymmetry etc. – – – – – – – – – –
Diagnosis
3 Major O O
2 Major +2 Minor O O O O O O O
Typical/Atypical Typical Typical Typical Typical Typical Typical Atypical Typical Typical Typical
*Evaluated for renal anomalies only in patients 6, 8, and 10;
?: renal ultrasonography not performed.
doi:10.1371/journal.pone.0067236.t002
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was adjusted. Persistence of the air-bone gap led to middle ear
exploration, and stapedotomy was performed because of impaired
stapes mobility. Despite multiple middle ear surgeries, hearing
gain could not be achieved and the patient is using hearing aids for
auditory rehabilitation. Bone conduction hearing was slightly
worsened on both sides after multiple surgeries, which was not
thought to be the result of middle ear manipulations. In patient 6,
incudostapedial joint was found fixed during middle ear explora-
tion, which led to the insertion of PORP after the removal of
incus. One year later, revision ossiculplasty was performed to
reposition the PORP but failed to close the air-bone gap.
Subsequently, cochlear implantation was performed on the same
side, which improved her hearing and language ability. During
cochlear implantation, the facial nerve dehiscence was seen at the
tympanic segment which ran anterosuperiorly to the stapes passing
superior to the round window. Perilymphatic gusher occurred
after cochleostomy but was easily controlled by conventional
methods. Two other patients (patients 8 and 10) had a history of
receiving two ossiculoplasties of the same ear and stapedotomy of
both ears, respectively, at other hospitals. Mixed hearing loss was
still observed in both of these patients despite middle ear
operations at the time of initial visit to our clinic. In another
patient (patient 9), a congenital cholesteatoma filling middle ear
space eroding incus and malleus was identified, and incus
interposition was performed after removal of cholesteatoma.
Closure of air-bone gap also failed in this patient who is currently
using hearing aids on both sides for auditory rehabilitation.
Mutation Analysis
All exons and exon-intron boundaries of EYA1, SIX1, and SIX5
genes were sequenced in 7 families with BOR/BO syndrome. One
missense and three splice site mutations were identified in EYA1,
while no mutations were found in either SIX1 or SIX5 gene
(Table 4–5). A novel missense mutation, p.E332G, was identified
in all four affected members of Family I, which caused an adenine
to guanine substitution at nucleotide position 965 converting
glutamic acid to glycine (Fig. 2A–B). This mutation changed the
charge of amino acids from a negative charge to nonpolar. The
conservation of the mutated amino acid was analyzed using the
CLC sequence viewer, which demonstrated that the glutamic acid
at amino acid position 332 is highly conserved in various
vertebrates (Fig. 2C). Three novel EYA1 splice site mutations,
c.1140+1 G.A, c.1598-2 A.C and c.699+5 G.A, were detect-
ed in 3 other families (Table 4, Fig. 3).
Splicing Assay
To investigate the potential pathogenic effect of the three novel
splice site mutations (c.1140+1 G.A, c.1598-2 A.C and
c.699+5 G.A) on normal splicing, each exon and the flanking
intronic sequences sufficient to allow splicing were inserted into a
pSPL3 or pSPL3b vector. Each vector was transfected into the
HeLa cells, and transcribed to mRNA in the cells. All three splice
site mutations were found to disrupt the normal splicing (Fig. 4).
Exons 12 (90 bp), 17 (101 bp), and 10 (140 bp), involved with
mutations c.1140+1 G.A, c.1598-2 A.C, and c.699+5 G.A,
respectively, were inserted between exon A (92 bp) and exon B
Figure 1. The findings of temporal bone CT in patient 7 and
normal control. (A–E) These images are temporal bone CT in patient
7. (A) Cochlear hypoplasia type III with less than two turns is indicated
by a black arrow. (B) The vestibular aqueduct (white asterisk) was
enlarged and seen in a circular shape in the axial view. The lateral
semicircular canal was slightly hypoplastic and the vestibular was
dilated (black arrowhead). (C) The facial nerve ran inferior to the
hypoplastic cochlea and displayed an obtuse angle between the
labyrinthine and tympanic segments (white arrowhead). (D) The
modiolus (white arrow) was present but defective and hypoplastic. (E)
The ossicular chain (white arrow) seen in the coronal view was
positioned in a different angle compared to the normal control. (F–K)
These images are temporal bone CT in normal control.
doi:10.1371/journal.pone.0067236.g001
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Table 3. Radiologic findings in patients with BO/BOR syndrome.
Patients TBCT MRI
Cochlea Vestibule VA ME FN IAC ED ES
1 CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) Bulbous (B)
2 CH (B) Dilated (B), LSCC
dysplasia (L)
Enlarged (B) Ossicular anomaly (B)Deviated (B) –
3 CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) –
4 CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) –
5* CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) Funnel (R) Enlarged (B) -
6* CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) – Enlarged (B) Enlarged (R)
7* CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) – Enlarged (B) Enlarged (L)
8 CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) Bulbous (L)
9 CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) Bulbous (B)
10* CH (B) Dilated (B) Enlarged (B) Ossicular anomaly (B)Deviated (B) Bulbous (L) Enlarged (B) -
*Patients who performed temporal MRI; TBCT = temporal bone computed tomography; MRI = temporal magnetic resonance imaging; CH= cochlear hypoplasia;
VA= vestibular aqueduct; ME =middle ear; FN = facial nerve; IAC = internal auditory canal; ED = endolymphatic duct; ES = endolymphatic sac; LSCC= lateral semicircular
canal.
doi:10.1371/journal.pone.0067236.t003
Figure 2. Identification of a novel missense mutation in the EYA1 gene. (A) Pedigree of family I comprised of two generations. Squares and
circles indicate females and males, respectively. Filled symbols display affected individuals and the arrow appoints the proband of the family. The
ages of the affected females are marked in years (Yr) next to the symbols. (B) Nucleotide sequence of exon 10 of the EYA1 gene. Black arrow indicates
the heterozygous nucleotide substitution, c.965 A.G, detected in the affected family members. (C) Multiple alignments of the EYA1 homologous
sequences of nine different vertebrates. The amino acid substituted by the missense mutation p.E332G (arrow) is highly conserved among the
different vertebrate species.
doi:10.1371/journal.pone.0067236.g002
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(171 bp) of the pSPL3 or pSPL3b vector. The size of the mutant
mRNA was 263 bp which included only exons A and B of the
vector, meaning that exon skipping occurred for all three splice site
mutations (Fig. 4). These results were confirmed by Sanger
sequencing showing that 263 bp of the mutant mRNA contained
only exons A and B of the vector (Fig. 4).
Identification of EYA1 Deletion
The MLPA analysis was performed in three patients (patients 8–
10) who were found not to carry any mutations in the three genes
(EYA1, SIX1 and SIX5) by direct sequencing, and the results were
compared to the data acquired in one normal control with normal
hearing confirmed by pure tone audiometry. The entire EYA1
gene was suspected to be deleted in patient 8 (Fig. 5). In this
patient, the peak height of all EYA1 probes was lower than half of
the reference peak, and the normalization ratio was approximately
0.5 compared with the reference values. In contrast, all 14 control
probes of the same patient located in other chromosomal regions
demonstrated values same as the reference peak with suitable
normalization ratios (0.8,1.2). The results of the MLPA indicated
that patient 8 had a heterozygous deletion encompassing the
whole EYA1 gene. To investigate the deleted region including
EYA1 in patient 8, genotype analysis using microsatellite markers
was performed. Only patient 8 revealed homozygous alleles for all
4 markers, while all 12 normal controls showed heterozygous
alleles for at least one of the microsatellite markers (Table S2). In
addition, genotypes for all 15 polymorphisms detected in the EYA1
gene were homozygous in patient 8 (Table 5). These results
strongly suggested that patient 8 carried a large deletion including
the whole EYA1 gene, although the range of the deleted
chromosomal region could not precisely be estimated.
Discussion
In this study, 5 of 7 unrelated Korean families clinically
diagnosed as BOR/BO syndrome were identified to carry
mutations in the EYA1 gene, including four novel intragenic
mutations and one large deletion encompassing the whole EYA1
gene. Pathogenic variations of the SIX1 and SIX5 genes were not
found in any of the patients. Clinically, auditory manifestations
known as the most common and characteristic feature of BOR/
BO syndrome were analyzed in detail together with the outcome
of various treatment modalities for hearing improvement such as
middle ear surgeries, cochlear implantations, or hearing aids.
Figure 3. Identification of three novel splice site mutations in the EYA1 gene. The nucleotide sequences of the control (WT/WT) and the
affected individuals (WT/MT) are shown for patients 5 (A), 6 (B), and 7 (C). Each heterozygous mutation is indicated by arrowheads. (A, C) The
mutations c.1140+ G.A and c.699+5 G.A are splicing donor site mutations of exons 12 and 10, respectively. (B) The mutation c.1598-2G.A is
splicing acceptor site mutation of exon 17.
doi:10.1371/journal.pone.0067236.g003
Table 4. Five novel mutations identified in EYA1 gene.
Families Patients Location Nucleotide change Amino acid change Type
I 1–4 Exon 10 c.965 A.G p.E322G Missense
II 5 Intron 12 c.1140+1 G.A – Splice site
III 6 Intron 16 c.1598-2 A.C – Splice site
IV 7 Intron 10 c.699+5 G.A – Splice site
V 8 Whole gene Large deletion
doi:10.1371/journal.pone.0067236.t004
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In contrast to the western population where large cohort studies
have been performed on BOR/BO syndrome, limited information
is available concerning genetic mutations of this syndrome in the
East Asian population, and a total of 16 mutations in the EYA1
gene have been reported including 7 nonsense, 3 frameshift, 3
splice-site, 2 missense mutations, and 1 partial deletion [17]. In
this study, EYA1 mutations were identified in 71% (5 of 7 families)
which is higher than 40% previously reported by Chang et al. [3].
Splice site mutations were the most common type found in 3 of 7
families, followed by one missense mutation and one large deletion
encompassing the whole EYA1 gene. In the Korean population,
there have been only 3 case reports of patients with BOR/BO
syndrome carrying EYA1 mutations, and this study adds to the
genotypic and phenotypic spectrum of BOR syndrome in the East
Asian population [15,21,22]. As for SIX1 mutations associated
with BOR/BO syndrome, more than 10 mutations have been
identified worldwide, while there is only one missense mutation
reported in the East Asian population [5,7,9,12,23,24]. Consis-
tently, no SIX1 or SIX5 mutation was found in this study
suggesting the limited role of SIX genes as the cause of BOR/BO
syndrome in the East Asian population. Since a large deletion was
identified by MLPA in one patient with BOR/BO syndrome, we
suggest that additional studies should be performed to identify
complex rearrangements or large deletions when no mutation is
found by conventional sequencing techniques.
No clear genotype-phenotype correlation could be demonstrat-
ed in this study in accordance with previous reports, in which no
mutation was found in a patient with all major features of BOR
syndrome (patient 9) whereas a splice site mutation of the EYA1
gene was identified in a patient presenting with only mixed
hearing loss and enlarged vestibular aqueduct (patient 7) [7]. Also,
no definite difference could be identified regarding the severity of
clinical features of BOR/BO syndrome or the presence of
additional phenotypes in the patient who carried a large deletion
encompassing the EYA1 gene (patient 8) compared to the patients
with intragenic EYA1 mutations.
The progression of hearing loss was variable in patients with
BOR/BO syndrome included in this study. Cremers et al. [19]
have reported that the hearing loss in BOR/BO syndrome was
stable without progression or fluctuation. However, half of the
patients included in this study demonstrated various degrees of
progressive hearing loss, and also sudden aggravation of hearing
was demonstrated in one patient. Kemperman et al. [25] have also
reported a patient with BOR syndrome showing progressive
hearing loss and suggested the correlation between the presence of
enlarged vestibular aqueduct and progressive fluctuant hearing
loss. In developmental studies, the expression of murine eya1 in the
sensory hair cells continued after birth and after maturation (P16
in mouse), suggesting an additional role for eya1 in the
differentiation and/or survival of the inner ear cell populations
in particular the sensory cells [26]. This may provide evidence for
the progression of hearing loss demonstrated in some of the
patients with EYA1 mutations considering the possible role of
EYA1 in the maintenance and survival of the hair cells and the
supporting cells. Therefore, we believe that the possibility of
hearing progression should be explained to the patients with
BOR/BO syndrome, and regular auditory tests should be
performed in order to treat these patients with proper modality
of auditory rehabilitation at an appropriate timing.
This study clearly demonstrated the limitation of middle ear
surgeries for hearing improvement in patients with BOR/BO
syndrome consistent with previous reports [19]. The failure may
be explained by several reasons. First, complex multiple anomalies
of the middle ear may have caused the persistence of air-bone gap
after simply reconstructing or modifying the ossicular chain by
performing ossiculoplasty or stapedotomy. Embryologically, mu-
rine eya1 has been reported to be expressed in the mesenchyme
surrounding the cartilage premordia of all three ossicles and also in
the epithelium of the tubotympanic recess which later develops
into the tympanic cavity at E13.5, meaning that mutation in the
EYA1 gene can disrupt normal development of the middle ear in
various aspects [26]. Decreased middle ear space, anomalies of the
oval and round windows, together with the abnormal angle of the
ossicles can all act as hindering factors for successful middle ear
surgeries. For example, abnormal angle of the stapes relative to the
tympanic membrane or abnormal position of the incus relative to
the stapes footplate can interrupt the proper positioning of the
middle ear prosthesis resulting in disturbance of sound transmis-
sion to the inner ear. Even in limited cases showing successful
hearing gain after middle ear surgeries, recurrence of air-bone gap
has been reported to occur, which may be related to the unstable
placement of the middle ear prosthesis inevitably caused by the
multiple structural abnormalities of the ossicles and the middle ear
cavity [19]. Secondly, vestibular aqueduct enlargement that was
seen in all of the patients in this study may have acted as a third
window causing the air-bone gap. As reported in previous studies,
air-bone gap caused by the third window effect cannot be
improved by middle ear explorations [27,28]. Third reason could
be related to the defective modiolus and enlarged internal auditory
canals often seen in these patients, which can be speculated to
cause increased perilymphatic pressure resulting in decreased
mobility of stapes and reduction of sound transmission. Since
typical clinical features of BOR/BO syndrome other than hearing
loss can be easily overlooked before performing initial middle ear
explorations and unsuccessful outcome may be encountered
unexpectedly, careful review of CT findings and history taking
as well as thorough physical examinations should always be
Table 5. Non-pathogenic polymorphisms detected in EYA1
and SIX5 genes.
Gene Location
Nucleotide
change
Amino acid
change Reference
EYA1 Intron 3 c.125-169T.C – rs.7840811
Intron 7 c.556+78T.A – –
Intron 8 c.639+39T.G rs3779747
Exon 9 c.813A.G p.T271T rs1445398
Intron 11 C.1050+107A.G – rs76660214
Intron 11 c.1050+113G.A – rs2053664
Exon 14 c.1278C.T p.G426G rs4738118
Intron 14 c.1360+53C.T – rs4737312
Intron 15 c.1476-21G.T – rs3735935
Intron 17 c.1699-55G.A – rs10103644
Intron 17 c.1699-23A.G – rs10090382
Exon 18 c.1755T.C p.H585H rs10103397
Intron 18 c.*509_
*512delAAAA
– rs146202037
Intron 18 c.*1324T.C – rs56115941
Intron 18 c.*1581G.A – rs9298163
SIX5 Intron 1 C.803+123C.A – rs3745802
Exon 3 c.1903C.T p.P635S rs.2014576
39 UTR c.*34G.A – –
doi:10.1371/journal.pone.0067236.t005
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performed in patients showing mixed hearing loss. In the future,
patients with BOR/BO syndrome may be good candidates of
active middle ear implants considering the failure of hearing gain
by conventional middle ear reconstruction techniques.
Since patients failed to gain hearing after one or more middle
ear surgeries, most of the patients in this study used bilateral
hearing aids. In two of the patients with severe to profound
hearing loss who could not benefit from hearing aids, cochlear
implantation was performed. In patients with syndromic hearing
loss, multiple factors have to be considered regarding auditory
rehabilitation, including combined mental retardation and devel-
opmental delay in addition to various inner ear malformations.
Cochlear implantation in patients with syndromic hearing loss is
challenging in both surgical and audiologic aspects. Although good
results of cochlear implantation have been reported in these
patients, some of the syndromes associated with cochlear nerve
deficiency or narrow internal auditory canals such as CHARGE
syndrome have shown limited outcome [29,30]. Although the
EYA1 gene is involved in the development of the spiral ganglion
and cochlear hypoplasia often seen in patients with BOR/BO
syndrome has been known to be a poor prognostic factor of
cochlear implantation, successful outcome in terms of speech and
auditory performances could be achieved in our patients after
cochlear implantation [26,31]. In addition, no surgical complica-
tions were encountered despite multiple inner ear and facial nerve
anomalies. Since there is limited data on the outcome of cochlear
implantation in patients with syndromic hearing loss, especially
BOR/BO syndrome, the results of this study may provide some
evidence for recommending cochlear implantation in patients with
BOR/BO syndrome who cannot benefit from hearing aids despite
the conductive component of hearing loss.
Conclusions
Considering the high mutation rate of the EYA1 gene in Korean
patients with BOR/BO syndrome, the mutational analysis of
EYA1 should be an integral part of the diagnosis of BOR/BO
syndrome in the East Asian population. The characteristic inner
ear and middle ear anomalies and mixed type hearing loss may
also provide clinical clues to suspect BOR/BO syndrome even in
the absence of other typical clinical features. The management of
hearing loss and auditory rehabilitation in BOR/BO syndrome
should be individually tailored keeping in mind the high failure
rate of hearing gain achieved by middle ear explorations in
patients with mixed hearing loss. Hearing aids are good options in
patients with mild to severe hearing loss, but regular hearing
evaluations are needed considering the possibility of progression of
hearing loss in order to treat these patients with proper modality of
auditory rehabilitation at an appropriate timing. Successful
outcome can be expected with cochlear implantations in patients
with BOR/BO syndrome who cannot benefit from hearing aids.
The novel EYA1 mutations identified in this study adds to the
genotypic and phenotypic spectrum of BOR syndrome in the East
Asian population and the clinical results of this study may provide
Figure 4. Splicing assays for the three novel splice site mutations in the EYA1 gene. The size of the amplified product of EYA1 minigene
transcripts of splice site mutations c.1140+1 G.A (A), c.1598-2 G.A (B), and c.699+5 G.A (C), were 263 bp which is smaller than that of the wild
type, suggesting exon skipping. The different splicing processes of the wild type and mutant transcripts are shown in a schematic illustration. Partial
nucleotide sequences of the wild and mutant types are presented. MOCK, MOCK vector; WT, wild type; MT, mutant type; NCT, negative control.
doi:10.1371/journal.pone.0067236.g004
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evidence for recommending proper means of auditory rehabilita-
tion in patients with BOR/BO syndrome.
Supporting Information
Figure S1 Temporal bone CT and temporal MRI
findings of patient 10 demonstrating enlarged vestibular
aqueduct in a circular shape. (A–F) Axial view of temporal
bone CT shows enlarged vestibular aqueduct (black arrows)
observed as a circular shape with a diameter significantly larger
than that of the posterior semicircular canal (black arrowhead in
Fig. S1A). (F–K) Axial view of temporal MRI also exhibited
enlargement of the endolymphatic duct (white arrows) whereas the
endolymphatic sac was not enlarged (white arrowhead in Fig.
S1K).
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